The aim of this paper is to review the most significant livestock-associated zoonoses. Human and animal health are intimately connected. This idea has been known for more than a century but now it has gained special importance because of the increasing threat from zoonoses. Zoonosis is defined as any infection naturally transmissible from vertebrate animals to humans. As the frequency and prevalence of zoonotic diseases increase worldwide, they become a real threat to public health. In addition, many of the newly discovered diseases have a zoonotic origin. Due to globalization and urbanization, some of these diseases have already spread all over the world, caused by the international flow of goods, people, and animals. However, special attention should be paid to farm animals since, apart from the direct contact, humans consume their products, such as meat, eggs, and milk. Therefore, zoonoses such as salmonellosis, campylobacteriosis, tuberculosis, swine and avian influenza, Q fever, brucellosis, STEC infections, and listeriosis are crucial for both veterinary and human medicine. Consequently, in the suspicion of any zoonoses outbreak, the medical and veterinary services should closely cooperate to protect the public health.

We review canine dietary supplements, in particular silymarin and its hepatoprotective properties. Dietary supplements should be considered complements to conventional drug treatments, helping to prevent health issues, such as nutritional deficiencies and organ dysfunctions. The market for veterinary supplements is growing rapidly. Pet owners are increasingly eager to provide their animals with the best care available. The rapidly growing market of supplements is an opportunity for both the industry and veterinarians, who can introduce new treatment protocols supported by dedicated dietary supplements. The liver is one organ that can be nutritionally supported in case of dysfunction. In dogs, hepatopathies may be primary or may be secondary to an underlying problem. Toxins, drugs, and neoplasia are reported among the causes of liver dysfunctions. There are several substances with proven liver-beneficial properties. One of these is silybin, a hepatoprotector extracted from Silybum marianum. Dietary supplementation with silybin seems a reasonable tool to support a core treatment for liver disease. Laboratory tests have additionally shown that silybin supplementation helps reduce liver damage. The literature indicates that silybin acts not only as an antioxidant, but also as an antifibrotic agent and a stimulator of cell regeneration. Due to its multidirectional action, it can effectively reduce liver damage, or help prevent it. Independent of the reason for its administration (prevention or therapy), it has been reported effective in laboratory animals, dogs, and humans. This was confirmed by an observational study performed at the University Center for Veterinary Medicine at Poznań University of Life Sciences. A total of 15 dogs with diagnosed liver conditions were supplemented with silybin for 30 days. Significant improvements were reported in the liver blood markers after the supplementation period. All things considered, silybin dietary supplementation is a noteworthy strategy in prevention and treatment of liver diseases in dogs.

Background Hepatopathies are an important group of disorders in dogs where proper nutritional care is crucial. Supplementation with a hepatoprotectant like silybin can improve liver function and should not interfere with nutrient digestibility. The purpose of this study was to investigate the effect of both pure silybin and commercial hepatoprotectant on nutrients digestibility, liver function indices and health status in healthy dogs (EXP1). Moreover, the second experiment (EXP2) investigated the effect of commercial hepatoprotectant on liver function tests and liver-associated miRNAs concentration in dogs with idiopathic liver disorder. Results Nutrient digestibility was not affected by treatment in EXP1. Supplementation did alter the serum fatty acid profile, with no clinical relevance. The levels of liver markers such as ALT, AST and GGT significantly decreased. In EXP2, supplementation with commercial hepatoprotectant containing silybin improved liver function tests. A decrease was observed in liver serum markers such as ALT, AST and miR122 concentration. Conclusions EXP1 confirmed that silybin (whether pure or as a commercial hepatoprotectant) does not interfere with digestion which subsequently exerts no detrimental effect on dogs’ health and metabolism. In EXP2, dietary supplementation with commercial hepatoprotectant containing silybin resulted in a decreased activity of serum liver markers, accompanied by a decrease in the concentration of liver-specific miRNA molecules. Liver function indices were consequently improved. Silybin supplementation can thus serve as an effective therapeutical tool in dogs with hepatopathies.

BackgroundHepatopathies are an important group of disorders in dogs, where proper nutritional care is crucial. Supplementation with a hepatoprotectant like silybin can improve liver performance, subsequently it should not interfere with nutrient digestibility. The purpose of the study was to investigate the effect of either pure silybin or commercial hepatoprotectant on nutrients digestibility, liver performance and health status in healthy dogs (EXP1). Moreover, the second experiment (EXP2) investigated the effect of commercial hepatoprotectant on liver laboratory test and liver-associated miRNA concentrations in dogs with idiopathic liver disorder. ResultsNutrient digestibility was not affected by treatment in EXP1. Supplementation did not affect serum fatty acid profile, with the exception of C20:5 n3. The levels of liver markers such as ALT, AST and GGT significantly decreased. In EXP2, supplementation with commercial hepatoprotectant containing silybin improved liver laboratory test. A decrease was observed in liver serum markers and miR122 concentration.ConclusionsEXP1 confirmed that silybin (whether pure or as a commercial hepatoprotectant) does not interfere with digestion and subsequently exerts no detrimental effect on dogs’ health and metabolism. In EXP2, dietary supplementation with commercial hepatoprotectant containing silybin resulted in decreased activity of serum liver markers, accompanied by a decrease in the concentration of liver-specific miRNA molecules. Liver performance was consequently improved. Silybin supplementation can thus serve as an effective therapeutical tool in dogs with hepatopathies.

This review aims to characterize promising novel markers of ovine mastitis. Mastitis is considered as one of the primary factors for premature culling in dairy sheep and has noticeable financial, productional, and animal welfare-related implications. Furthermore, clinical, and subclinical mammary infections negatively affect milk yield and alter the milk composition, thereby leading to lowered quality of dairy products. It is, therefore, crucial to control and prevent mastitis through proper diagnosis, treatment or culling, and appropriate udder health management particularly at the end of the lactation period. The clinical form of mastitis is characterized by abnormalities in milk and mammary gland tissue alteration or systemic symptoms consequently causing minor diagnostic difficulties. However, to identify ewes with subclinical mastitis, laboratory diagnostics is crucial. Mastitis control is primarily dependent on determining somatic cell count (SCC) and the California Mastitis Test (CMT), which aim to detect the quantity of cells in the milk sample. The other useful diagnostic tool is microbial culture, which complements SCC and CMT. However, all mentioned diagnostic methods have their limitations and therefore novel biomarkers of ovine subclinical mastitis are highly desired. These sensitive indicators include acute-phase proteins, miRNA, and cathelicidins measurements, which could be determined in ovine serum and/or milk and in the future may become useful in early mastitis diagnostics as well as a preventive tool. This may contribute to increased detection of ovine mammary gland inflammation in sheep, especially in subclinical form, and consequently improves milk quality and quantity.